Silas Inman

New York, United States

Senior Vice President, Content at CURE Magazine

Senior Vice President, Content at Pharmacy Times

Senior Vice President, Content at OncLive

Chief Brand Officer @MJHLifeSciences focused on innovative, audience-driven results @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more

Articles

BCG Plus Mitomycin Shows Similar Efficacy, Fewer Doses in NMIBC

5 days ago | targetedonc.com | Silas Inman

The combination of Bacillus Calmette-Guérin (BCG) plus intravesical mitomycin showed similar efficacy and safety to that of BCG alone for patients with non–muscle-invasive bladder cancer (NMIBC); however, it showed an added benefit of using 40% fewer BCG doses than the monotherapy arm, according to data from the phase 3 ANZUP 1301 trial (NCT02948543) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC

6 days ago | onclive.com | Silas Inman

Adjuvant pembrolizumab (Keytruda) demonstrated prolonged disease-free survival (DFS) and overall survival (OS) compared with placebo in patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis from the phase 3 KEYNOTE-564 trial (NCT03142334) presented at the 2025 ASCO Annual Meeting.
Mitomycin/BCG Combo Could Alleviate BCG Shortage Concerns for NMIBC

6 days ago | onclive.com | Silas Inman

The intravesical combination of BCG plus mitomycin showed similar efficacy and safety to that of BCG alone for patients with non–muscle-invasive bladder cancer (NMIBC) but with the added benefit of using 40% fewer BCG doses than the monotherapy arm, according to findings from the phase 3 ANZUP 1301 trial (NCT02948543) presented at the 2025 ASCO Annual Meeting.
Cilta-Cel Benefit Consistent Across High-Risk Subgroups of Multiple Myeloma

6 days ago | cgtlive.com | Silas Inman

Ciltacabtagene autoleucel (cilta-cel; Carvykti) improved progression-free survival (PFS) and overall survival (OS) compared with standard of care (SOC) across all subgroups of patients with relapsed/refractory multiple myeloma, including in those with extramedullary disease (EMD) and regardless of prior lines of therapy, according to a subgroup analyses from the phase 3 CARTITUDE-4 trial (NCT04181827) presented at the 2025 ASCO Annual Meeting.
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection

6 days ago | ajmc.com | Silas Inman

Detection and treatment of cancer in earlier stages remain a key strategy for improving outcomes; however, typical screening methods are commonly ineffective or nonexistent for some types of cancer. The long-desired "holy grail" of cancer detection would be a single test that could seamlessly detect cancer during a routine health check-up.
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

1 week ago | urologytimes.com | Silas Inman

Adjuvant treatment with pembrolizumab (Keytruda) continued to show consistent overall survival (OS) and disease-free survival (DFS) benefits compared with placebo for patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis of the phase 3 KEYNOTE-564 study (NCT03142334) presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL

1 week ago | onclive.com | Silas Inman

Treatment with the ROR1-targeted antibody-drug conjugate (ADC) zilovertamab vedotin in combination with rituximab and gemcitabine-oxaliplatin (R-GemOx) resulted in an objective response rate (ORR) of 56.3% for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to findings from the dose confirmation portion of the phase 2/3 waveLINE-003 study (NCT05139017) presented at the 2025 ASCO Annual Meeting.
CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL

1 week ago | cgtlive.com | Silas Inman

KITE-363 elicited responses in nearly all patients with relapsed/refractory large B-cell lymphoma (LBCL) who were treated with the dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, according to data from a phase 1 study (NCT04989803) presented at the 2025 ASCO Annual Meeting. For the single-arm dose escalation study, KITE-363 was administered at 3 dose levels (DL), with the largest dose selected for further study.
Multiple Myeloma Treatment: The Price of Success

1 month ago | managedhealthcareexecutive.com | Silas Inman

May 5, 2025MHE PublicationMHE May 2025The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of treatment high. Editor's note: This is expanded version of an article that was posted as part of coverage of the 2025AMCP Annual Meeting. The treatment of multiple myeloma is often described as complicated or complex.
GLP-1 Side Effects Have a Side Effect on Pharmacy Costs| AMCP Annual 2025

2 months ago | managedhealthcareexecutive.com | Silas Inman

Glucagon-like peptide 1 (GLP-1) treatment resulted in side effects that often required additional medications, increasing overall pharmacy use and costs among GLP-1 drugs compared with nonusers, according to a real-world claims analysis completed by Blue Cross Blue Shield Association (BCBSA) and Blue Health Intelligence (BHI) that was presented as a poster at the annual meeting of the Academy of Managed Care Pharmacy in Houston this week When excluding the costs of the GLP-1 drugs themselves,...